Korea’s Shin Poong Pharmaceutical Cuts Biotech Deal With France’s LFB Biotechnologies
This article was originally published in PharmAsia News
Executive Summary
Shin Poong and LFB agreed to set up a joint-venture biotech plant in Korea for sales of LFB biotech products in other countries
You may also be interested in...
European Regulatory Round Up: While EMA Opens Up, European Pharma Battens Down For Tough Year
The European Medicines Agency is focusing on transparency and pharmacovigilance over the next year, while the pharmaceutical industry is gearing up for a fight against austerity measures.
Korea's Shin Poong Seeks EMEA Special Approval For Anti-malarial Drug Pyramax
SEOUL - Local South Korean drug maker Shin Poong Pharmaceutical submitted a new drug application to the European Medicines Agency for its new artemisinin combination therapy Pyramax (pyronaridine-artesunate) for malaria
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.